Tysabri gains Crohn's disease indication

The FDA has approved the use of Tysabri (natalizumab, from Biogen Idec) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies. Due to the serious adverse events associated with Tysabri treatment, patients, prescribers, pharmacies, and infusion centers must all be enrolled in a special restricted distribution program called the Crohn's Disease-Tysabri Outreach Unified Commitment to Health (CD-TOUCH) Prescribing Program.

Tysabri is already indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis (MS).

For more information call (800) 456-2255 or visit www.tysabri.com.